Obesity
Latest News
Docs weigh in on insurance coverage for obesity medications
“We would not see the spate of coverage restrictions if we were talking about heart disease or cancer; insurers can get away with this because...
From the Journals
Scientists find the ‘on’ switch for energy-burning brown fat
Activating brown fat could trigger “signals that help coordinate whole-body energy metabolism.”
From the Journals
Metformin, weight management to stop type 2 diabetes in kids
“Weight stabilization and metformin therapy could be important interventions for diabetes prevention in children.”
Conference Coverage
New ‘twincretin’ pemvidutide: Another option for obesity
“We need to look at the person holistically and at other aspects of cardiometabolic health and treat in a personalized way and choose treatments...
Conference Coverage
Are they ‘antiobesity medications’ or ‘weight-loss drugs’?
“We believe that the common use of the term ‘weight-loss medications’ by media and the public, as well as by doctors and the scientific community...
Conference Coverage
Semaglutide win in HFpEF with obesity regardless of ejection fraction: STEP-HFpEF
It remains unknown, however, “whether the improvement in health status, functional status, and reduced inflammation” will translate to reduced...
Feature
The new word in liver disease: The story behind NAFLD’s rebranding as MASLD
“There are tons of these patients who were not being considered before. Now they’re in a category by themselves, where they are going to be able...
Conference Coverage
Weight loss with semaglutide maintained for up to 3 years
“Importantly, these effects were sustained for up to 3 years, supporting the use of once weekly semaglutide for the long-term management of type 2...
Commentary
When to prescribe semaglutide?
When considering an antiobesity medication for a patient, it’s important to discuss efficacy, side-effect profile, contraindications, cost and...
News from the FDA/CDC
FDA gives semaglutide two drug safety–related label changes
The second addition concerns a new adverse reaction that was identified during the postmarketing experience: gastrointestinal ileus, an intestinal...
Commentary
The ‘triple-G’ agonist for obesity management: Five things to know
Results from a phase 2 trial published in June 2023 showed a weight loss of 24%...